Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 5/20 | 0.42 |
| ▸ | CA12 | O43570 | 4/20 | 0.42 |
| ▸ | CA1 | P00915 | 4/20 | 0.42 |
| ▸ | CA4 | P22748 | 4/20 | 0.42 |
| ▸ | CA9 | Q16790 | 4/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | GLP1R | P43220 | 8/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20226534 | 0.96 | MEN1 (0.49) | MEN1KMT2ACA2CA12CA1 | |
| SCHEMBL25812337 | 0.95 | MEN1 (0.46) | MEN1KMT2ACA2CA12CA1 | |
| SCHEMBL26167787 | 0.93 | KMT2A (0.54) | MEN1KMT2ACA2CA12CA1 | |
| SCHEMBL16532922 | 0.93 | MEN1 (0.46) | MEN1KMT2ACA2CA12CA1 | |
| SCHEMBL12145805 | 0.93 | MEN1 (0.46) | MEN1KMT2ACA2CA12CA1 | |
| SCHEMBL21043286 | 0.93 | MEN1 (0.46) | MEN1KMT2ACA2CA12CA1 | |
| SCHEMBL26878210 | 0.92 | KMT2A (0.45) | MEN1KMT2ACA2CA12CA1 | |
| SCHEMBL13253969 | 0.92 | MEN1 (0.45) | MEN1KMT2ACA2CA12CA1 | |
| SCHEMBL26878205 | 0.92 | KMT2A (0.45) | MEN1KMT2ACA2CA12CA1 | |
| SCHEMBL26878200 | 0.92 | KMT2A (0.45) | MEN1KMT2ACA2CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170174722-A1 | LLP2A-BISPHOSPHONATE CONJUGATES FOR OSTEOPOROSIS TREATMENT | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174722-A1 | LLP2A-BISPHOSPHONATE CONJUGATES FOR OSTEOPOROSIS TREATMENT | LCP1, BST2, ITGA2B | MEN1 1824/4885KMT2A 950/4885CA2 3873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.